Starzl T E, Weil R, Koep L J, Iwaki Y, Terasaki P I, Schröter G P
Surg Gynecol Obstet. 1979 Dec;149(6):815-21.
Twenty-seven consecutive recipients of cadaveric kidneys, including five with pre-existing warm cytotoxic antibodies, were treated with thoracic duct drainage before and after transplantation. Fourteen patients who had lymph drainage for 26 to 58 days before transplantation had minor cytotoxic antibody responses after grafting, even if the antibodies had been present before therapy. Only one of the 14 recipients had any rejection during the follow-up periods of one to six months. There were two deaths. The 13 patients pretreated for 17 to 23 days exhibited stronger cytotoxic antibody responsiveness, and five of these recipients had significant rejections of which four were reversible. One of the latter 13 patients died. These clinical and immunologic studies have established the value and have defined the appropriate timing of preoperative thoracic duct drainage in kidney transplantation. They have also directed attention to the rationale andthe probable value of using other immunosuppressive methods for preparatory host conditioning instead of beginning such therapy at the time of transplantation.
27例连续接受尸体肾移植的患者,包括5例术前即存在温反应性细胞毒性抗体的患者,在移植前后均接受了胸导管引流治疗。14例在移植前进行了26至58天淋巴引流的患者,即使在治疗前就已存在抗体,移植后细胞毒性抗体反应也较轻。在1至6个月的随访期内,这14例受者中只有1例发生了排斥反应。有2例死亡。13例术前接受了17至23天治疗的患者表现出更强的细胞毒性抗体反应性,其中5例受者发生了严重排斥反应,4例可逆转。后13例患者中有1例死亡。这些临床和免疫学研究确定了肾移植术前胸导管引流的价值并明确了合适的时机。它们还引导人们关注使用其他免疫抑制方法进行宿主预处理的基本原理和可能的价值,而不是在移植时才开始此类治疗。